| 名稱 | CCT245737 |
| 描述 | CCT245737 is an orally active, selective Chk1 inhibitor with an IC50 of 1.3 nM, and is >1,000-fold selective over CHK2 and CDK1. |
| 細(xì)胞實(shí)驗(yàn) | Cytotoxicity is determined as the drug concentration that gives 50% inhibition of tumour cell proliferation (GI50) using a 96 h Sulforhodamine B (SRB) assay. Inhibition of intracellular CHK1 activity is measured using a cell-based ELISA for the abrogation of an etoposide-induced G2 checkpoint (mitosis induction assay, MIA). The IC50 for G2 checkpoint abrogation (MIA) is determined in the presence of nocodazole using UCN01 as a positive control. The activity index (AI) is used as a measure of the compounds ability to induce mitosis relative to its toxicity (i.e., ratio of MIA IC50: 96 h SRB GI50). Routine potentiation studies are carried out using a fixed concentration (GI50) of either gemcitabine or SN38 in combination with a range of CCT245737 concentrations to determine the combination GI50 of CCT245737. The ability of CCT245737 to enhance gemcitabine or SN38 cell killing is expressed as a potentiation index (PI) equal to the ratio of the GI50 for CCT245737 alone versus the combination GI50 for CCT245737. PI values > 1 indicate the potentiation of the genotoxic activity. In addition, a series of experiments is carried out using fixed, non- or minimally toxic concentrations of CCT245737 (≤GI20) with a range of different concentrations of gemcitabine or SN38 to determine the extent to which CCT245737 enhances drug cytotoxicity compared with the genotoxic agent alone, i.e. conventional PI (ratio GI50 genotoxic alone: GI50 genotoxic combined with non-toxic CCT245737 concentration, Con PI)[2]. |
| 激酶實(shí)驗(yàn) | Commercial in vitro 33P radiometric kinase assays is carried out against 124 human kinases using 10 μM CCT245737 at ATP concentrations corresponding to the kinase Km, ATP [2]. |
| 動物實(shí)驗(yàn) | Human HT29 colorectal carcinoma cells are injected s.c into the flanks of female NCr athymic mice 6-8 weeks of age. Dosing commenced 5 days after transplantation when tumours reach a mean diameter of 5.5 mm. Gemcitabine (100 mg/kg i.v.) is dosed in saline on days 0, 7 and 14 and compounds 4 (CCT245737) and 41 (150 mg/kg p.o.) in 10% DMSO 20% PEG 400, 5% Tween 80, 65% water, 24 and 48 h after each dose of gemcitabine. Tumours are measured and body weights recorded three times weekly. Animals are culled on an individual basis when tumours reach a predetermined humane endpoint (mean diameter <15 mm)[1]. |
| 體外活性 | 方法： CCT245737（0.01,0.05,0.1,0.5，1,2,5,24小時(shí)） 處理 K562 細(xì)胞，WseternBlot檢測CHK1總表達(dá)的蛋白；用 VP16 （5 μM）、CCT245737 （5 μM） 或 VP16 和 CCT245737（0.01,0.05,0.1,0.5，1,2,5,24小時(shí)）的組合處理的K562 細(xì)胞，進(jìn)行的蛋白質(zhì)印跡分析。
結(jié)果：增加 CCT245737 濃度并未顯著降低 CHK1 總蛋白水平，并且 CHK1 僅在高濃度 CCT245737 （5 μM） 下被抑制；CCT245737可以通過抑制VP16誘導(dǎo)的CHK1在Ser296自磷酸化并促進(jìn)VP16處理的K562細(xì)胞中DNA損傷的積累來有效抑制CHK1的激活。[3] |
| 體內(nèi)活性 | 方法：CCT245737（10mg/kg，靜脈注射/口服）給藥小鼠后，檢測體內(nèi)的藥代動力學(xué)。
結(jié)果：靜脈注射CCT245737血藥峰濃度為4μmol/，半衰期為2.86h，AUC為9.96μmol.h/L，血漿清除率為2.1L/h/kg，分布容積大（0.19L）；等效的口服劑量與 AUC 幾乎相同，顯示完全口服生物利用度（F = 105%）。[1] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : 5 mg/mL
H2O : Insoluble
DMSO : 50 mg/mL (131.81 mM)
|
| 關(guān)鍵字 | CCT 245737 | CCT-245737 | SRA-737 | Inhibitor | inhibit | SRA 737 | CCT245737 | Checkpoint Kinase (Chk) |
| 相關(guān)產(chǎn)品 | BX795 | ANI-7 | Prexasertib dihydrochloride | CCT241533 hydrochloride | CHIR-124 | Prexasertib | Rabusertib | CHK1-IN-4 hydrochloride | Baricitinib | CHK1-IN-3 | PD0166285 | A-443654 |
| 相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | ReFRAME 相關(guān)化合物庫 | 激酶抑制劑庫 | 高選擇性抑制劑庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |